Neutrolis

Executive Summary

Neutrolis is a clinical-stage biotechnology company pioneering first-in-class precision therapies that target Neutrophil Extracellular Traps (NETs)—a pathological driver of tissue damage in autoimmune and inflammatory diseases. Based in Cambridge, MA, the company leverages its proprietary platform to engineer molecules that disassemble NETs, addressing root causes rather than symptoms. Neutrolis entered Phase 1 clinical development in 2025, focusing on a lead candidate for a defined autoimmune indication. The company's approach is differentiated by its focus on extracellular DNA-mediated pathology, which is implicated in conditions such as lupus, vasculitis, and rheumatoid arthritis. With a novel mechanism of action and a clear unmet medical need, Neutrolis aims to provide disease-modifying benefits where current standard of care is limited to symptom management. As of early 2026, Neutrolis is progressing its Phase 1 study, with initial safety and biomarker data expected in the coming quarters. The company operates in a competitive landscape of autoimmune therapeutics but occupies a unique niche in NET-targeting. Upcoming catalysts include the release of Phase 1 results, which will inform dose selection and pathway activation for Phase 2, as well as potential strategic partnerships to expand pipeline assets. Given the early-stage nature and high-risk profile, the near-term execution on clinical milestones will be critical for value inflection. Neutrolis has the potential to become a leader in NET-mediated disease modulation if clinical validation is achieved.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 clinical data readout for lead NET-targeting candidate30% success
• Q4 2026Initiation of Phase 2 clinical trial in a targeted autoimmune indication50% success
• Q1 2027Strategic partnership or licensing deal for pipeline expansion20% success